
Third-Party Tested · CoA Available
$249.99
30 MG
Stock & Save



Add to Cart
ABOUT THIS COMPOUND
GLP-3 RT is the research name for retatrutide. It acts on three receptors at once: GLP-1, GIP, and glucagon. Research has examined how it affects metabolism, energy use, and blood sugar in study models. Most similar compounds hit only two receptors. The third target is what sets this one apart.
Triple GLP-1/GIP/glucagon receptor agonist peptide (LY3437943)
FORMULA
C221H342N50O68
FORM
Lyophilized powder
MOLECULAR WEIGHT
4731.32 g/mol
CAS / ID
LY3437943 (CAS 2381089-83-2)
VERIFIED
Quantified by reverse-phase HPLC; identity confirmed by mass spectrometry.
An independent laboratory certificate accompanies every order.
If a lot doesn’t match its Certificate of Analysis, we make it right.
All orders ship within 24-48 hours on business days.
Peer-reviewed research
Sources & References
2023
NEW ENGLAND JOURNAL OF MEDICINE
Triple-Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial
2023
DOI: 10.1056/NEJMoa2301972
Jastreboff AM, et al.
View Source
August 7
2023
NEW ENGLAND JOURNAL OF MEDICINE
Triple-Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial
2023
DOI: 10.1056/NEJMoa2301972
Jastreboff AM, et al.
View Source
August 7
2023
NEW ENGLAND JOURNAL OF MEDICINE
Triple-Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial
2023
DOI: 10.1056/NEJMoa2301972
Jastreboff AM, et al.
View Source
August 7
2023
NEW ENGLAND JOURNAL OF MEDICINE
Triple-Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial
2023
DOI: 10.1056/NEJMoa2301972
Jastreboff AM, et al.
View Source
August 7
Common Questions
Before You Order
Common Questions


























